<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00328120</url>
  </required_header>
  <id_info>
    <org_study_id>D6995C00004</org_study_id>
    <secondary_id>9238IL/0062</secondary_id>
    <nct_id>NCT00328120</nct_id>
  </id_info>
  <brief_title>Faslodex 500mg Multiple Dose Tolerability Study in BC Patients</brief_title>
  <official_title>An Open, Multicentre Phase I Clinical Study to Assess the Tolerability of Fulvestrant 500 mg in Postmenopausal Women With Hormone Receptor Positive Advanced or Recurrent Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the tolerability of 500mg fulvestrant in
      postmenopausal women with hormone receptor positive, advanced or recurrent breast cancer
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">April 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective of this study is to assess the tolerability of 500mg fulvestrant</measure>
    <time_frame>assessed when all patients have been in the study for 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>each visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>assessed when all patients have been in the study for 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>assessed when all patients have been in the study for 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate</measure>
    <time_frame>assessed when all patients have been in the study for 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response</measure>
    <time_frame>assessed when all patients have been in the study for 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of response and changes in serum tumour markers</measure>
    <time_frame>assessed when all patients have been in the study for 6 months</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">20</enrollment>
  <condition>Advanced Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fulvestrant</intervention_name>
    <description>500 mg intramuscular injection</description>
    <other_name>Faslodex</other_name>
    <other_name>ZD9238</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of written informed consent

          -  Postmenopausal woman who fulfils any one of the following criteria:

          -  Histological or cytological confirmation of breast cancer

          -  Estrogen receptor positive (ER+) or progesterone receptor positive (PgR+).

        Exclusion Criteria:

          -  Having received any one of the following therapy for advanced or recurrent breast
             cancer

          -  2 or more regimens of hormonal therapy or immunotherapy or 2 or more regimens of
             chemotherapy, etc
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Breast Cancer Established Brands Team Medical Science Director, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nagoyata</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2006</study_first_submitted>
  <study_first_submitted_qc>May 18, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2006</study_first_posted>
  <last_update_submitted>November 16, 2010</last_update_submitted>
  <last_update_submitted_qc>November 16, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 17, 2010</last_update_posted>
  <keyword>Advanced breast cancer</keyword>
  <keyword>Faslodex</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fulvestrant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

